Literature DB >> 20697761

3D-QSAR and molecular docking studies of azaindole derivatives as Aurora B kinase inhibitors.

Ping Lan1, Wan-Na Chen, Ping-Hua Sun, Wei-Min Chen.   

Abstract

The Aurora kinases have been regarded as attractive targets for the development of new anticancer agents. Recently a series of azaindole derivatives with Aurora B inhibitory activities were reported. To explore the relationship between the structures of substituted azaindole derivatives and their inhibition of Aurora B, 3D-QSAR and molecular docking studies were performed on a dataset of 41 compounds. 3D-QSAR, including CoMFA and CoMSIA, were applied to identify the key structures impacting their inhibitory potencies. The CoMSIA model showed better results than CoMFA, with r(2)(cv) value of 0.575 and r(2) value of 0.987. 3D contour maps generated from CoMFA and CoMSIA along with the docking binding structures provided enough information about the structural requirements for better activity. Based on the structure-activity relationship revealed by the present study, we have designed a set of novel Aurora B inhibitors that showed excellent potencies in the developed models. Thus, our results allowed us to design new derivatives with desired activities.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20697761     DOI: 10.1007/s00894-010-0820-7

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  26 in total

1.  Discovery of a new series of Aurora inhibitors through truncation of GSK1070916.

Authors:  Jesus R Medina; Seth W Grant; Jeffrey M Axten; William H Miller; Carla A Donatelli; Mary Ann Hardwicke; Catherine A Oleykowski; Qiaoyin Liao; Ramona Plant; Hong Xiang
Journal:  Bioorg Med Chem Lett       Date:  2010-03-01       Impact factor: 2.823

2.  CoMFA and molecular docking studies of benzoxazoles and benzothiazoles as CYP450 1A1 inhibitors.

Authors:  Jie Pan; Gen-Yan Liu; Jin Cheng; Xin-Jie Chen; Xiu-Lian Ju
Journal:  Eur J Med Chem       Date:  2009-11-26       Impact factor: 6.514

3.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Authors:  Andrew A Mortlock; Kevin M Foote; Nicola M Heron; Frédéric H Jung; Georges Pasquet; Jean-Jacques M Lohmann; Nicolas Warin; Fabrice Renaud; Chris De Savi; Nicola J Roberts; Trevor Johnson; Cyril B Dousson; George B Hill; David Perkins; Glenn Hatter; Robert W Wilkinson; Stephen R Wedge; Simon P Heaton; Rajesh Odedra; Nicholas J Keen; Claire Crafter; Elaine Brown; Katherine Thompson; Stephen Brightwell; Liz Khatri; Madeleine C Brady; Sarah Kearney; David McKillop; Steve Rhead; Tony Parry; Stephen Green
Journal:  J Med Chem       Date:  2007-03-21       Impact factor: 7.446

4.  Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis.

Authors:  Jiaying Sun; Shaoxi Cai; Ning Yan; Hu Mei
Journal:  Eur J Med Chem       Date:  2009-11-27       Impact factor: 6.514

5.  3D QSAR studies on ketoamides of human cathepsin K inhibitors based on two different alignment methods.

Authors:  Xulin Pan; Ninghua Tan; Guangzhi Zeng; Huoqiang Huang; He Yan
Journal:  Eur J Med Chem       Date:  2009-11-11       Impact factor: 6.514

6.  Docking and 3D-QSAR studies of 7-hydroxycoumarin derivatives as CK2 inhibitors.

Authors:  Na Zhang; Rugang Zhong
Journal:  Eur J Med Chem       Date:  2009-10-13       Impact factor: 6.514

7.  Aurora kinase inhibitor ZM447439 induces apoptosis via mitochondrial pathways.

Authors:  Minglun Li; Anke Jung; Ute Ganswindt; Patrizia Marini; Anna Friedl; Peter T Daniel; Kirsten Lauber; Verena Jendrossek; Claus Belka
Journal:  Biochem Pharmacol       Date:  2009-08-15       Impact factor: 5.858

8.  The selective Aurora B kinase inhibitor AZD1152 as a novel treatment for hepatocellular carcinoma.

Authors:  Arihiro Aihara; Shinji Tanaka; Mahmut Yasen; Satoshi Matsumura; Yusuke Mitsunori; Ayano Murakata; Norio Noguchi; Atsushi Kudo; Noriaki Nakamura; Koji Ito; Shigeki Arii
Journal:  J Hepatol       Date:  2009-10-29       Impact factor: 25.083

9.  CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists.

Authors:  Elena Cichero; Sara Cesarini; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2009-10-01       Impact factor: 1.810

10.  The discovery of the potent aurora inhibitor MK-0457 (VX-680).

Authors:  David Bebbington; Hayley Binch; Jean-Damien Charrier; Simon Everitt; Damien Fraysse; Julian Golec; David Kay; Ronald Knegtel; Chau Mak; Francesca Mazzei; Andrew Miller; Michael Mortimore; Michael O'Donnell; Sanjay Patel; Francoise Pierard; Joanne Pinder; John Pollard; Sharn Ramaya; Daniel Robinson; Alistair Rutherford; John Studley; James Westcott
Journal:  Bioorg Med Chem Lett       Date:  2009-05-03       Impact factor: 2.823

View more
  4 in total

1.  Some insights into the binding mechanism of Aurora B kinase gained by molecular dynamics simulation.

Authors:  Rui Xiong; Xiao-Mei Cai; Jing Wei; Peng-Yu Ren
Journal:  J Mol Model       Date:  2012-05-30       Impact factor: 1.810

2.  Benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one derivatives as Aurora A kinase inhibitors: LQTA-QSAR analysis and detailed systematic validation of the developed model.

Authors:  Ashish M Kanhed; Radha Charan Dash; Nishant Parmar; Tarun Kumar Das; Rajani Giridhar; Mange Ram Yadav
Journal:  Mol Divers       Date:  2015-07-17       Impact factor: 2.943

3.  Pyrrolo[3,2-d]pyrimidine derivatives as type II kinase insert domain receptor (KDR) inhibitors: CoMFA and CoMSIA studies.

Authors:  Xiao-Yun Wu; Wen-Hua Chen; Shu-Guang Wu; Yuan-Xin Tian; Jia-Jie Zhang
Journal:  Int J Mol Sci       Date:  2012-02-22       Impact factor: 6.208

Review 4.  The azaindole framework in the design of kinase inhibitors.

Authors:  Jean-Yves Mérour; Frédéric Buron; Karen Plé; Pascal Bonnet; Sylvain Routier
Journal:  Molecules       Date:  2014-11-28       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.